<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute coronary syndromes: Approach to nonculprit lesions</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute coronary syndromes: Approach to nonculprit lesions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute coronary syndromes: Approach to nonculprit lesions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Dawn Abbott, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Serge Korjian, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H470454977"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For many patients with myocardial infarction (MI), coronary angiography with stenting improves outcomes. Usually, the lesion responsible for the infarct, often referred to as the "culprit lesion," is readily identified by electrocardiography and angiography and is treated with balloon angioplasty or stenting. In addition to culprit lesions, patients with MI may have one or more obstructive lesions remote from the area of infarction referred to as "nonculprit" lesions.</p><p>This topic will address the management of nonculprit lesions in patients with ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).</p><p>Other aspects of percutaneous coronary intervention in patients with acute coronary syndromes (ACS) can be found separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">"Periprocedural bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/81.html" rel="external">"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction"</a>.)</p><p></p><p class="headingAnchor" id="H2905483429"><span class="h1">TERMINOLOGY</span></p><p class="headingAnchor" id="H2957504629"><span class="h2">Culprit lesions</span><span class="headingEndMark"> — </span>A culprit lesion is the site within the epicardial coronary circulation where blood flow has been acutely interrupted or significantly reduced leading to MI and usually occurs at the site of atherosclerotic plaque rupture or thrombus formation. In addition, the presence of thrombus identifies a lesion as high-risk.</p><p class="headingAnchor" id="H787245747"><span class="h2">Nonculprit lesions</span><span class="headingEndMark"> — </span>Lesions that are not clearly contributing to acute infarction but may be flow-limiting are referred to as nonculprit lesions. The hemodynamic significance of such lesions may be determined by angiographic assessment, intracoronary pressure measurements, or noninvasive stress testing. (See <a class="local">'Assessment of nonculprit lesion anatomy'</a> below.)</p><p class="headingAnchor" id="H13010751"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In addition to a culprit lesion, 40 to 60 percent of patients with STEMI have multivessel coronary artery disease (CAD) with other significant lesions (≥50 percent luminal narrowing at the time of angiography or fractional flow reserve &lt;0.80) [<a href="#rid1">1,2</a>]. Patients with ACS and significant multivessel CAD have higher rates of mortality and reinfarction than those with single-vessel disease [<a href="#rid3">3,4</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 2082 patients undergoing primary percutaneous coronary intervention, the one-year cumulative incidence of death for patients with single-, double-, and triple-vessel disease was 3.2, 4.4, and 7.8 percent (p = 0.003), respectively. The adverse impact of multivessel disease due to nonculprit lesions raises the question as to whether revascularization of these nonculprit lesions could improve outcomes [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In studies of patients with STEMI and a nonculprit chronic total occlusion (CTO) lesion, mortality was generally higher than in patients without a CTO [<a href="#rid5">5,6</a>].</p><p></p><p class="headingAnchor" id="H4092942517"><span class="h1">ASSESSMENT OF NONCULPRIT LESION ANATOMY</span><span class="headingEndMark"> — </span>The approach to nonculprit percutaneous coronary intervention (PCI) in patients with MI is determined by the type of lesion, the severity of stenosis, and the number and location of residual obstructive lesions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stenosis severity</strong> – Visual estimation of stenosis severity with angiography is typically sufficient. If the severity of stenosis is uncertain (eg, some lesions with 50 to 69 percent visual stenosis), intracoronary fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) measurements can be used to determine the severity stenosis. If FFR or iFR is used to assess nonculprit lesion severity, we use cut-off values &lt;0.80 for FFR or &lt;0.89 for iFR. (See  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements", section on 'Intermediate severity stenosis'</a>.)</p><p></p><p class="bulletIndent1">FFR was not routinely used in trials that evaluated the effect of nonculprit PCI, and one trial found similar results among patients who underwent nonculprit PCI guided by angiographic assessment or by FFR assessment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction (FLOWER-MI) study was a multicenter randomized controlled trial (n = 1171) that examined whether complete revascularization guided by FFR was superior to an angiography-guided procedure in patients with STEMI and multivessel disease following successful primary PCI [<a href="#rid7">7</a>]. The primary outcome (mortality, nonfatal MI, unplanned hospitalization with urgent revascularization) was similar in the FFR-guided and angiography-guided groups (5.5 versus 4.2 percent; hazard ratio 1.32, 95% CI 0.78-2.23).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesion complexity</strong> – We evaluate for the presence of lesions that are technically difficult to address including bifurcation lesions, stenosis of the left main coronary artery, and chronic total occlusion. The approach to such lesions is discussed below. (See <a class="local">'Complex lesions, chronic total occlusions'</a> below.)</p><p></p><p class="bulletIndent1">Further details on issues intrinsic to these and other complex lesions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">"Percutaneous coronary intervention of specific coronary lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left main or multivessel disease</strong> – The approach to nonculprit PCI is influenced by whether the residual lesions are amenable to coronary artery bypass graft surgery (CABG; eg, left main stenosis, two- or three-vessel CAD). The details on the characteristics of anatomy amenable to CABG are discussed separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Left main disease (See  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two- or three-vessel disease (See  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Multivessel disease'</a>.)</p><p></p><p class="headingAnchor" id="H3353736170"><span class="h1">ROLE OF NONCULPRIT PCI IN SPECIFIC SCENARIOS</span></p><p class="headingAnchor" id="H1042478539"><span class="h2">Unfavorable scenarios for immediate nonculprit PCI</span><span class="headingEndMark"> — </span>In patients who underwent percutaneous coronary intervention (PCI) of culprit lesions and who have residual nonculprit lesions, we reassess the patient to determine the risks and benefits of additional PCI of nonculprit lesions  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). Though PCI or coronary artery bypass graft surgery (CABG) may be an option for therapy in the future, we do not immediately perform nonculprit PCI in the following scenarios:</p><p class="headingAnchor" id="H108099451"><span class="h3">Cardiogenic shock</span><span class="headingEndMark"> — </span>We recommend not performing nonculprit lesion PCI in patients with MI and cardiogenic shock  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). While culprit lesion PCI in patients with cardiogenic shock is beneficial, a randomized trial suggested that immediate nonculprit PCI in similar patients is associated with harm:</p><p class="bulletIndent1"><span class="glyph">●</span>In the CULPRIT-SHOCK trial, which included 685 patients with STEMI or NSTEMI, culprit-only PCI had a lower risk of all-cause mortality compared with culprit plus nonculprit PCI (43 versus 52 percent; hazard ratio [HR] 0.84, 95% CI 0.72-0.98) [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H1733969552"><span class="h3">Anatomy amenable to bypass grafting</span><span class="headingEndMark"> — </span>In stable patients with STEMI or NSTEMI who have nonculprit lesions amenable to CABG (eg, three-vessel CAD, left main CAD), we perform a comprehensive evaluation for revascularization rather than proceed with immediate PCI  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). The approach to choosing a revascularization strategy in the presence of left main or multivessel disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H4145364586"><span class="h3">Complex lesions, chronic total occlusions</span><span class="headingEndMark"> — </span>The approach to patients with ACS who have nonculprit stenoses that are complex (eg, complex bifurcation anatomy or chronic total occlusion [CTO]) is individualized and depends on the specific anatomy, the likelihood of technical success, and the risk of complications  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). If we plan to perform PCI in patients with such lesions, we generally stage the PCI intervention rather than perform it during primary PCI. (See  <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">"Percutaneous coronary intervention of specific coronary lesions", section on 'Chronic total occlusion'</a>.)</p><p>Our approach is motivated by the higher likelihood of complications associated with CTO interventions, and observational studies suggest that the benefit of CTO PCI shortly after the index MI is unclear [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The EXPLORE trial randomly assigned 204 patients with STEMI to PCI of CTO within seven days of primary PCI or no PCI of the CTO lesion [<a href="#rid10">10</a>]. Procedural success occurred in 73 percent of cases. At four months, there was no clear difference in the primary endpoints of mean left ventricular ejection fraction (44.1 versus 44.8 percent) and mean left ventricular end-diastolic volume (216 versus 213 mL) as assessed by cardiovascular magnetic resonance imaging.</p><p></p><p class="headingAnchor" id="H2453822668"><span class="h3">Other unfavorable scenarios</span><span class="headingEndMark"> — </span>Other scenarios in which the risk of the procedure or the benefit to the patient are generally not in favor of immediate nonculprit PCI include  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Less than Thrombolysis In Myocardial Infarction (TIMI) III grade flow in the nonculprit vessel after culprit PCI. (See  <a class="medical medical_review" href="/z/d/html/81.html" rel="external">"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled bleeding or other complication after PCI of the culprit lesion. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk of contrast nephropathy, adverse sedation effects, or radiation exposure injury. (See  <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">"Prevention of contrast-associated acute kidney injury related to angiography", section on 'Major risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of patient, operator, or healthcare team fatigue.</p><p></p><p class="headingAnchor" id="H1190104335"><span class="h2">Approach to nonculprit PCI</span><span class="headingEndMark"> — </span>In patients who do not have contraindications to additional PCI after PCI of culprit lesions, the decision to perform PCI of nonculprit lesions and the timing of such PCI is based on the type of MI:</p><p class="headingAnchor" id="H2305874614"><span class="h3">STEMI</span><span class="headingEndMark"> — </span>In patients who are stable after PCI of culprit lesions and who have anatomy amenable to PCI, we recommend performing PCI of all significant nonculprit lesions rather than PCI guided by additional tests for ischemia (eg, invasive coronary physiology, noninvasive stress testing), symptoms of ischemia, PCI after discharge, or not performing PCI of nonculprit lesions  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). For most patients, we suggest complete revascularization during the index procedure rather than as a staged procedure.</p><p>This approach is consistent with professional guidelines [<a href="#rid11">11,12</a>].</p><p>Our approach is primarily influenced by trials in which nonculprit lesion PCI in patients with STEMI who are not candidates for CABG reduced the risk of subsequent MI and meta-analyses of older trials that suggest a small mortality benefit. Once the decision to perform nonculprit PCI is made and if feasible, it is reasonable to perform PCI during the index procedure; this approach reduces the burden to the patient inherent to separate (ie, staged) procedures and, as demonstrated in trials, reduces the risk of recurrent MI associated with staged procedures. The evidence includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonculprit PCI versus no plan for additional PCI</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The FIRE trial, which included 1445 patients age 75 years or older with STEMI or NSTEMI (65 percent) who were not candidates for CABG, found that PCI of nonculprit lesions guided by physiology reduced the rate of all-cause death (9.2 versus 12.8 percent; HR 0.7, 95% CI 0.51-0.96) and MI (4.4 versus 7.0 percent; HR 0.62, 95% CI 0.4-0.97) compared with no plan for nonculprit artery PCI [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the COMPLETE trial, 4041 patients with STEMI and multivessel disease who had undergone successful culprit lesion PCI were assigned to either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization (culprit-only group) [<a href="#rid14">14</a>]. Patients with anatomy amenable to CABG were excluded. An angiographically significant lesion was defined by the presence of at least 70 percent stenosis on visual estimation or if there was 50 to 69 percent visual stenosis and a fractional flow reserve measurement of 0.80 or less. The following results were found at a median follow-up of three years. The rate of MI was lower in the complete revascularization group (5.4 versus 7.9 percent; HR 0.68, 95% CI 0.53-0.86) as was ischemia-driven revascularization (1.4 versus 7.9 percent; HR 0.18, 95% CI 0.12-0.26). All-cause and cardiovascular mortality were similar between the two groups. Notably, patients enrolled in the trial had a relatively low SYNTAX score of approximately 16, indicating that the chances for successful PCI were relatively high.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In meta-analyses, there was a consistent finding of lower rates of cardiovascular mortality, recurrent MI, and repeat revascularization with nonculprit lesion PCI [<a href="#rid15">15,16</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A 2020 meta-analysis found that nonculprit PCI was associated with lower risks of cardiovascular death (relative risk [RR] 0.68, 95% CI 0.47-0.98), MI (RR 0.65, 95% CI 0.54-0.79), and unplanned revascularization (RR 0.37, 95% CI 0.28-0.51) [<a href="#rid15">15</a>]. In addition, there were similar risks of major bleeding and contrast-induced nephropathy between the two groups.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In another meta-analysis, patients who underwent nonculprit PCI had lower risks of cardiovascular death (HR 0.62, 95% CI 0.39-0.97), MI (HR 0.68, 95% CI 0.55-0.84), and revascularization (HR 0.29, 95% 0.22-0.38) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of nonculprit PCI</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial (MULTISTARS) that included 418 patients with STEMI, patients assigned to complete revascularization immediately after the culprit artery PCI had lower rates of nonfatal MI (2 versus 5.3 percent; HR 0.36, 95% CI 0.16-0.8) and unplanned ischemia-driven revascularization (4.1 versus 9.3 percent; HR 0.42, 95% CI 0.24-0.74) but similar rates of mortality compared with patients assigned to complete revascularization 19 to 45 days after the index PCI [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The BIOVASC trial investigated the timing of PCI for nonculprit lesions in patients with STEMI or NSTEMI using a noninferiority design [<a href="#rid18">18</a>]. Patients were assigned to complete revascularization during the index hospital stay (n = 764) or to complete revascularization after the index hospital stay but within six weeks (n = 761). PCI of nonculprit lesions prior to discharge decreased the rate of the secondary outcomes of MI (1.9 versus 4.5 percent; HR 0.41, 95% CI 0.22-0.76) and unplanned ischemia-driven revascularization (4.2 versus 6.7 percent; HR 0.61, 95% CI 0.39-0.95). For the outcome of MI, the difference between groups was evident within days after randomization, which suggests that PCI before discharge prevented such events in the interval immediately after the index MI. The rates of cardiovascular and all-cause death were similar in each group.</p><p></p><p class="headingAnchor" id="H661668426"><span class="h3">NSTEMI</span><span class="headingEndMark"> — </span>In patients with NSTEMI who undergo PCI of culprit lesions but who have residual nonculprit lesions, we suggest performing PCI of all significant nonculprit lesions, either angiography- or physiology-guided, during the index admission, rather than performing PCI guided by additional testing for ischemia (eg, coronary physiology study, noninvasive stress imaging) or symptoms of ischemia, not performing PCI of nonculprit lesions, or performing PCI after discharge  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). If feasible, performance of nonculprit PCI during the index procedure may avoid the need for a separate PCI procedure.</p><p>Professional guidelines relevant to patients with NSTEMI either do not comment directly on nonculprit PCI or favor early nonculprit PCI [<a href="#rid11">11,12</a>].</p><p>Our approach is based on direct data from the BIOVASC trial and indirect data from trials that evaluated nonculprit revascularization in patients with STEMI. Another small trial suggested that PCI immediately following culprit PCI and PCI before discharge had similar outcomes. The data include:</p><p class="bulletIndent1"><span class="glyph">●</span>The BIOVASC trial included patients with NSTEMI; the benefit of early revascularization on reducing recurrent MI did not differ based on the patient's initial presentation [<a href="#rid18">18</a>]. Additional details of this trial are presented elsewhere in this topic. (See <a class="local">'STEMI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The SMILE trial randomly assigned 584 patients with NSTEMI to nonculprit lesion PCI during the initial PCI or to nonculprit lesion prior to discharge [<a href="#rid19">19</a>]. The rates of mortality and MI were similar between the two groups, while target vessel revascularization was higher in the delayed PCI group (8.3 versus 15.2 percent). All patients underwent revascularization before discharge; the short time between PCI in the two groups may have resulted in similar rates of recurrent MI.</p><p></p><p class="headingAnchor" id="H1463611726"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H470455019"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – In addition to a culprit lesion, 40 to 60 percent of patients with ST-elevation myocardial infarction (STEMI) have multivessel coronary artery disease (CAD) with other significant lesions. The presence of such lesions increases the likelihood of mortality and reinfarction. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of nonculprit PCI in specific scenarios – </strong>After culprit lesion percutaneous coronary intervention (PCI), a decision must be made on how to manage any remaining nonculprit lesions. The decision to revascularize such lesions depend on the following factors  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unfavorable scenarios for immediate nonculprit PCI</strong> – Though PCI or coronary artery bypass graft surgery (CABG) may be an option for therapy in the future, immediate nonculprit PCI is typically not performed in the following scenarios:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Presence of cardiogenic shock</strong> – We recommend <strong>not</strong> performing nonculprit lesion PCI in patients with myocardial infarction (MI) and cardiogenic shock (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>)  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). While culprit lesion PCI in patients with cardiogenic shock is beneficial, a randomized trial suggested that nonculprit PCI in similar patients is associated with harm. (See <a class="local">'Cardiogenic shock'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anatomy amenable to coronary artery bypass grafting</strong> –In stable patients with STEMI or non-ST-elevation MI (NSTEMI) who have nonculprit lesions amenable to CABG (eg, three-vessel CAD, left main CAD), we perform a comprehensive evaluation for revascularization rather than proceed with PCI. The approach to choosing a revascularization strategy in the presence of left main or multivessel disease is discussed separately  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Complex lesions, chronic total occlusions </strong>– If we plan to perform PCI in patients with complex lesions, including chronic total occlusions (CTO), we generally stage the PCI intervention rather than perform it during primary PCI  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). (See <a class="local">'Complex lesions, chronic total occlusions'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Other unfavorable scenarios –</strong> Other scenarios in which the risk of the procedure or the benefit to the patient are generally not in favor of nonculprit PCI include less than Thrombolysis In Myocardial Infarction (TIMI) III grade flow in the culprit vessel after optimal PCI; uncontrolled bleeding or other major complication after PCI of the culprit lesion; high risk of contrast nephropathy, adverse sedation effects, or radiation exposure injury; and presence of patient, operator, or healthcare team fatigue  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). (See <a class="local">'Other unfavorable scenarios'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach to patients without contraindications to additional PCI </strong>–<strong> </strong>In patients who do not have contraindications to additional PCI, the decision to perform PCI of nonculprit lesions and the timing of such PCI is determined by the presence of unstable lesions characteristics or, in the absence of unstable lesions, the clinical presentation:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>ST-elevation myocardial infarction</strong> – In patients who are stable after PCI of culprit lesions and who have anatomy amenable to PCI, we recommend performing PCI of all significant nonculprit lesions rather than PCI guided by additional tests for ischemia or symptoms of ischemia, PCI after discharge, or not performing PCI of nonculprit lesions (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>)  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). For most patients, we suggest complete revascularization during the index procedure rather than as a staged procedure (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'STEMI'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Non-ST-elevation myocardial infarction</strong> – In patients with NSTEMI who undergo PCI of culprit lesions but who have residual nonculprit lesions, we suggest performing PCI of all significant nonculprit lesions during the index admission rather than perform PCI guided by additional testing for ischemia or symptoms of ischemia or not performing PCI of nonculprit lesions (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef142898" href="/z/d/graphic/142898.html" rel="external">algorithm 1</a>). (See <a class="local">'NSTEMI'</a> above.)</p><p></p><p class="headingAnchor" id="H633999079"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Sorajja, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rasoul S, Ottervanger JP, de Boer MJ, et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009; 20:415.</a></li><li><a class="nounderline abstract_t">Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA 2014; 312:2019.</a></li><li><a class="nounderline abstract_t">Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397.</a></li><li><a class="nounderline abstract_t">Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007; 28:1709.</a></li><li><a class="nounderline abstract_t">van der Schaaf RJ, Claessen BE, Vis MM, et al. Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock. Am J Cardiol 2010; 105:955.</a></li><li><a class="nounderline abstract_t">Claessen BE, Dangas GD, Weisz G, et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J 2012; 33:768.</a></li><li><a class="nounderline abstract_t">Puymirat E, Cayla G, Simon T, et al. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. N Engl J Med 2021; 385:297.</a></li><li><a class="nounderline abstract_t">Thiele H, Akin I, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017; 377:2419.</a></li><li><a class="nounderline abstract_t">Christakopoulos GE, Christopoulos G, Carlino M, et al. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions. Am J Cardiol 2015; 115:1367.</a></li><li><a class="nounderline abstract_t">Henriques JP, Hoebers LP, Råmunddal T, et al. Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial. J Am Coll Cardiol 2016; 68:1622.</a></li><li><a class="nounderline abstract_t">Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e18.</a></li><li><a class="nounderline abstract_t">Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40:87.</a></li><li><a class="nounderline abstract_t">Biscaglia S, Guiducci V, Escaned J, et al. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med 2023; 389:889.</a></li><li><a class="nounderline abstract_t">Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med 2019; 381:1411.</a></li><li><a class="nounderline abstract_t">Ahmad Y, Howard JP, Arnold A, et al. Complete Revascularization by Percutaneous Coronary Intervention for Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: An Updated Meta-Analysis of Randomized Trials. J Am Heart Assoc 2020; 9:e015263.</a></li><li><a class="nounderline abstract_t">Pavasini R, Biscaglia S, Barbato E, et al. Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2020; 41:4103.</a></li><li><a class="nounderline abstract_t">Stähli BE, Varbella F, Linke A, et al. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med 2023; 389:1368.</a></li><li><a class="nounderline abstract_t">Diletti R, den Dekker WK, Bennett J, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet 2023; 401:1172.</a></li><li><a class="nounderline abstract_t">Sardella G, Lucisano L, Garbo R, et al. Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. J Am Coll Cardiol 2016; 67:264.</a></li></ol></div><div id="topicVersionRevision">Topic 103273 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19641460" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399277" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862409" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556348" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346312" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240495" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33999545" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29083953" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784515" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27712774" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34882435" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165437" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2018 ESC/EACTS Guidelines on myocardial revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37634150" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31475795" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Complete Revascularization with Multivessel PCI for Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476540" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Complete Revascularization by Percutaneous Coronary Intervention for Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: An Updated Meta-Analysis of Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31891653" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37634190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36889333" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26796390" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
